综合冷冻消融与免疫治疗联合治疗转移性肝细胞癌。
Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer.
机构信息
Surgical Department, Fuda Cancer Hospital, Jinan University School of Medicine, Guangzhou 510665, Guangdong Province, China.
出版信息
World J Gastroenterol. 2013 Jun 14;19(22):3473-80. doi: 10.3748/wjg.v19.i22.3473.
AIM
To retrospectively assess the effect of comprehensive cryosurgery (ablation of intra- and extra-hepatic tumors) plus dendritic cell-cytokine-induced killer cell immunotherapy in metastatic hepatocellular cancer.
METHODS
We divided 45 patients into cryo-immunotherapy (21 patients), cryotherapy (n = 12), immunotherapy (n = 5) and untreated (n = 7) groups. Overall survival (OS) after diagnosis of metastatic hepatocellular cancer was assessed after an 8-year follow-up.
RESULTS
Median OS was higher following cryo-immunotherapy (32 mo) or cryotherapy (17.5 mo; P < 0.05) than in the untreated group (3 mo) and was higher in the cryo-immunotherapy group than in the cryotherapy group (P < 0.05). In the cryo-immunotherapy group, median OS was higher after multiple treatments (36.5 mo) than after a single treatment (21 mo; P < 0.05).
CONCLUSION
Cryotherapy and, especially, cryo-immunotherapy significantly increased OS in metastatic hepatocellular cancer patients. Multiple cryo-immunotherapy was associated with a better prognosis than single cryo-immunotherapy.
目的
回顾性评估综合冷冻消融术（肝内和肝外肿瘤消融）加树突状细胞-细胞因子诱导的杀伤细胞免疫疗法治疗转移性肝癌的效果。
方法
我们将 45 名患者分为冷冻免疫治疗组（21 例）、冷冻治疗组（n = 12）、免疫治疗组（n = 5）和未治疗组（n = 7）。经过 8 年的随访，评估转移性肝癌诊断后的总生存期（OS）。
结果
冷冻免疫治疗组（32 个月）或冷冻治疗组（17.5 个月；P < 0.05）的中位 OS 均高于未治疗组（3 个月），且冷冻免疫治疗组高于冷冻治疗组（P < 0.05）。在冷冻免疫治疗组中，多次治疗（36.5 个月）的中位 OS 高于单次治疗（21 个月；P < 0.05）。
结论
冷冻治疗，尤其是冷冻免疫治疗显著提高了转移性肝癌患者的 OS。多次冷冻免疫治疗比单次冷冻免疫治疗的预后更好。
Zotero 插件